IQVIA Reports Second Quarter 2026 Earnings Exceeding Guidance
IQVIA Holdings Inc. announced its second quarter 2026 financial results during an earnings call, with revenue, adjusted EBITDA, and adjusted diluted earnings per share all surpassing the high end of the company’s guidance range. Ari Bousbib, Chairman and Chief Executive Officer, alongside Mike Fedock, Executive Vice President and Chief Financial Officer, detailed the company’s operational performance for the quarter.
Revenue and Earnings Growth Reach Upper Guidance Limits
Total revenue for the second quarter reached growth of 8.7 percent on a reported basis, while constant currency growth landed at 8.5 percent. Adjusted EBITDA increased by 9.2 percent year-over-year. Adjusted diluted earnings per share hit $3.15, representing a 12.1 percent increase from the same period last year. Bousbib stated during the call that the financial beat resulted entirely from strong operational performance.
Clinical Research Segment Generates 3.15 Billion in Bookings
The R&DS segment posted organic revenue growth of 7 percent and total revenue growth of nearly 9 percent. Net new bookings totaled $3.15 billion, marking a 19 percent year-over-year increase and a 27 percent sequential gain. This activity produced a quarterly book-to-bill ratio of 1.22. Bousbib noted that trailing 12-month net new bookings have increased in each of the past four quarters for the long-cycle business.
Segment Reporting Structure and Forward-Looking Cautions
Management referenced a new segment reporting structure implemented on January 1, 2026, which required the recasting of prior period segment amounts. Kerri Joseph, Senior Vice President of Investor Relations and Treasury, and management reminded listeners that forward-looking statements carry risks and uncertainties detailed in Securities and Exchange Commission filings, including annual reports on Form 10-K. The company also discussed non-GAAP financial measures as a supplement to GAAP figures.
Frequently Asked Questions About the Earnings Call
What were the specific financial guidance beats for the quarter?
Total revenue, adjusted EBITDA, and adjusted diluted earnings per share all exceeded the high end of management’s forecasted range, with adjusted diluted EPS reaching $3.15.
How did the Research and Development Solutions segment perform?
The R&DS segment delivered organic revenue growth of 7 percent alongside $3.15 billion in net new bookings and a quarterly book-to-bill ratio of 1.22.
When did IQVIA adopt its current financial reporting structure?
The company implemented a new segment reporting structure on January 1, 2026, recasting prior period segment amounts to conform with the updated format.
Related reading